PROCEPT BioRobotics Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from PROCEPT BioRobotics Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 96% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 95% of Healthcare companies in United States.
- Cash Locked Ratio: For every $100 of sales, $44 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $45 tied up three years earlier. More money tied up than 87% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-6.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 54% of Healthcare companies in United States.
Cash Locked Ratio
$44For every $100 of sales, $44 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $45 tied up three years earlier.
More money tied up than 87% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
−$4Sales grew 311% in 3 years, but profit fell: $4 less profit per $100 of extra sales.
Lower than 71% of Healthcare companies in United States.
Asset Productivity Ratio
+311% / +64%In 3 years sales changed by +311% while total assets changed by +64%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-22.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 56% of Healthcare companies in United States.
Cash Cushion Ratio
+18%Cash, after subtracting all debt, equals 18% of its market value (net cash).
Higher than 61% of Healthcare companies in United States.
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 95% of Healthcare companies in United States.
Tangible Net Worth Ratio
100%Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 96% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
PROCEPT BioRobotics Corporation made a loss over the last year. PROCEPT BioRobotics Corporation owes $0.29 for every $1 it owns. PROCEPT BioRobotics Corporation made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossPROCEPT BioRobotics Corporation made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.35The share price is 3.35 times PROCEPT BioRobotics Corporation's book value per share, higher than 59% of Healthcare companies in United States.
Market cap
$1.1 BThe total market value of all of PROCEPT BioRobotics Corporation's shares at today's price (share price × number of shares), larger than 66% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$340 MWhat PROCEPT BioRobotics Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$5.97Net worth divided by the number of shares. The share price of $20.03 is 3.4 times this, which is the P/B above.
Return on equity (ROE)
-30.2%PROCEPT BioRobotics Corporation lost 30.2% of its shareholders' money over the last year, higher than 60% of Healthcare companies in United States.
Owes vs Owns
0.29×PROCEPT BioRobotics Corporation owes $0.29 for every $1 it owns (low), lower than 61% of Healthcare companies in United States.
Dividend yield
NonePROCEPT BioRobotics Corporation does not currently pay a dividend.
Revenue growth
+37%Revenue rose 37% in the year to Dec 2025, and grew 60% a year on average over 3 years.
Profit growth
LossPROCEPT BioRobotics Corporation made a loss in each of the last two years.
Profit margin
-31.0%PROCEPT BioRobotics Corporation lost $31 for every $100 of revenue.
Interest cover
Not coveredPROCEPT BioRobotics Corporation's operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashPROCEPT BioRobotics Corporation held $208 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For PROCEPT BioRobotics Corporation: $1.1 B ÷ $340 M (30 Jun 2026) = 3.4.
What is PROCEPT BioRobotics Corporation's return on equity?
PROCEPT BioRobotics Corporation lost 30.2% of its shareholders' money over the last year, higher than 60% of Healthcare companies in United States.
How much does PROCEPT BioRobotics Corporation owe compared with what it owns?
PROCEPT BioRobotics Corporation owes $0.29 for every $1 it owns (low), lower than 61% of Healthcare companies in United States.
Does PROCEPT BioRobotics Corporation pay a dividend?
No. PROCEPT BioRobotics Corporation does not currently pay a dividend.
Is PROCEPT BioRobotics Corporation's revenue growing?
Revenue rose 37% in the year to Dec 2025, and grew 60% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.